We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$3.17B
AUM Growth
+$561M
Cap. Flow
+$1.16B
Cap. Flow %
36.62%
Top 10 Hldgs %
63.1%
Holding
323
New
68
Increased
74
Reduced
74
Closed
84

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$37.9M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$24.5M
3
MRK icon
Merck
MRK
+$12.3M
4
GILD icon
Gilead Sciences
GILD
+$11.7M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$11.6M

Top Sells

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$16.4M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$9.99M
3
TSLA icon
Tesla
TSLA
+$7.93M
4
LRMR icon
Larimar Therapeutics
LRMR
+$4.64M
5
OCUL icon
Ocular Therapeutix
OCUL
+$3.33M

Sector Composition

Rank Sector Weight
1 Miscellaneous 89.52%
2 Healthcare 9.63%
3 Energy 0.42%
4 Industrials 0.14%
5 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$803B
$156M 4.93%
7,588
+3,202
+73% +$644K
BIIB icon
2
CALL
Biogen
BIIB
$32.1B
$155M 4.91%
4,580
+400
+10% +$129K
BMY icon
3
CALL
Bristol-Myers Squibb
BMY
$131B
$146M 4.62%
24,763
+15,629
+171% +$881K
GILD icon
4
PUT
Gilead Sciences
GILD
$182B
$115M 3.63%
12,185
-1,618
-12% -$167K
VRTX icon
5
PUT
Vertex Pharmaceuticals
VRTX
$132B
$114M 3.6%
9,592
– –
ACAD icon
6
CALL
Acadia Pharmaceuticals
ACAD
$4.74B
$90.1M 2.84%
+28,364
New +$804K
ABBV icon
7
CALL
AbbVie
ABBV
$454B
$83.7M 2.64%
12,792
+5,185
+68% +$327K
OEF icon
8
PUT
iShares S&P 100 ETF
OEF
$20.2B
$65.7M 2.08%
5,494
+205
+4% +$18.3K
PFE icon
9
PUT
Pfizer
PFE
$158B
$64.8M 2.05%
+21,936
New +$629K
AGN
10
CALL
DELISTED
Allergan plc
AGN
$59.7M 1.88%
2,318
+785
+51% +$196K
VRTX icon
11
CALL
Vertex Pharmaceuticals
VRTX
$132B
$46.1M 1.46%
3,881
-18,788
-83% -$2.12M
LLY icon
12
CALL
Eli Lilly
LLY
$1.01T
$44.2M 1.4%
6,405
+2,046
+47% +$138K
PFE icon
13
Pfizer
PFE
$158B
$39.1M 1.23%
+1,322,658
New +$37.9M
AGN
14
CALL
DELISTED
Allergan Inc
AGN
$31.9M 1.01%
1,500
+1,359
+964% +$270K
AZN icon
15
PUT
AstraZeneca
AZN
$254B
$30.5M 0.96%
4,338
-301
-6% -$21.6K
ACAD icon
16
Acadia Pharmaceuticals
ACAD
$4.74B
$27.4M 0.87%
+864,437
New +$24.5M
AGN
17
PUT
DELISTED
Allergan plc
AGN
$25.9M 0.82%
1,006
-1,002
-50% -$250K
UTHR icon
18
CALL
United Therapeutics
UTHR
$21.3B
$25.7M 0.81%
1,981
+1,111
+128% +$143K
PFE icon
19
CALL
Pfizer
PFE
$158B
$24.3M 0.77%
8,229
+2,790
+51% +$80K
IOC
20
PUT
DELISTED
Interoil Corporation
IOC
$21.9M 0.69%
4,481
+131
+3% +$7K
OPK icon
21
CALL
Opko Health
OPK
$1.16B
$21.8M 0.69%
21,847
-476
-2% -$4.07K
COV
22
PUT
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$19.5M 0.62%
1,911
+999
+110% +$95.8K
AZN icon
23
CALL
AstraZeneca
AZN
$254B
$17.6M 0.56%
2,503
+1,000
+67% +$71.6K
MRK icon
24
PUT
Merck
MRK
$357B
$17.2M 0.54%
3,173
+241
+8% +$13.4K
AGN
25
DELISTED
Allergan plc
AGN
$16.8M 0.53%
65,181
+2,948
+5% +$737K
1
2 3 4 5

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2014 Portfolio in Review

As of Q4 2014, Sabby Management held 323 positions worth $3.17B, up 22% from $2.6B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $1.16B of net new capital in Q4 2014, opening 68 new positions and adding to 74 existing holdings. Its largest new stake was Pfizer: 1,322,658 shares worth $39.1M.

By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 92% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Larimar Therapeutics, an estimated $4.64M trimmed.

  • Sabby Management's largest Q4 2014 buy was Pfizer: 1,322,658 shares worth $39.1M.
  • Sabby Management added most to Achillion Pharmaceuticals in Q4 2014, an estimated $11.6M increase.
  • Sabby Management's biggest Q4 2014 reduction was Larimar Therapeutics, cutting an estimated $4.64M.
  • Sabby Management fully exited Acadia Healthcare in Q4 2014, selling an estimated $16.4M.
  • Sabby Management's ten largest holdings make up 63% of its $3.17B portfolio in Q4 2014.
  • Sabby Management opened 68 new positions and closed 84 in Q4 2014.
  • Sabby Management's portfolio value rose 22% quarter-over-quarter to $3.17B.

Based on Sabby Management's 13F filing for Q4 2014, filed 17 Feb 2015.